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INTRODUCTION
Inflammatory diseases of the liver and gastrointestinal tract are characterized by a dense leukocyte infiltration of stromal tissue in the liver, biliary system, or in the intestinal wall, with subsequent gradual development of fibrosis [1] . This massive leukocyte invasion, in combination with production of antibodies targeting autoantigens, forms the basis of autoimmune inflammation. Detection of antibodies targeting liver-related or non-organ specific antigens is an important diagnostic tool in the recognition of autoimmune conditions of the liver and gut and are associated with a severe course of disease and unfavorable prognosis [1] . Despite their diagnostic relevance, the pathogenetic role of autoantibodies in the induction of tissue damage remains unclear.
Several mechanisms are involved in the pathogenesis of autoimmunity, including impairment of antigen presentation, T cell regulation, and humoral control [2] . Indeed, proliferation of autoreactive T cell clones in combination with insufficient numbers of CD4 + CD25 + regulatory T cells have been reported in patients with autoimmune hepatitis (AIH) [3] , primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) [2] , although the role of autoimmunity in Crohn's disease (CD) was recently questioned [4] .
Resistin, also known as FIZZ3 (found in inflammatory zone 3) or ADSF (adipocytespecific secretory factor) is a 12.5 kDa cystein-rich peptide with inter-cellular signalling activity. The cystein-rich C-terminal sequence of resistin identifies a specific signature of the resistin-like molecules (RELM) [5] . This protein family comprises four members (RELMα, RELMβ, RELMγ and resistin), which all exhibit unique tissue distribution patterns in different mammalian species [6] [7] [8] [9] . Resistin was originally described in context with its role in carbohydrate metabolism in rodents [9] . In humans, resistin is active in inflammatory processes and can be found at places of leukocyte infiltration [10] . Resistin is secreted by mononuclear leukocytes and neutrophils following proinflammatory stimuli such as endotoxins, IL-6 or TNF [11] . Treatment of target cells with resistin initiates intracellular activation of the NF-kB pathway, resulting in the expression of a broad spectrum of pro-inflammatory cytokines [11] .
Resistin has been studied in streptococcal infections [12] and sepsis [13] , and was assumed to contribute to the pathologic inflammatory responses associated with severe infections. Recently, however, possible protective roles for RELM in persistent cervical human papillomavirus infection [14] and gastrointestinal worm infection [15] have been suggested. Resistin is also abundant in many inflammatory conditions, such as rheumatoid arthritis [10, 11] , systemic lupus erythematosus [16] and primary Sjögren's syndrome [17] . Furthermore, raised levels of resistin have been reported in patients with IBD, more specifically in CD and ulcerative colitis (UC) [18] [19] [20] [21] . Studies on autoimmune [22] and viral hepatitis [23] showed increased circulating levels of resistin in proportion to liver tissue damage assessed by aminotransferases [22] , but not in relation to steatosis or stage of fibrosis [23] . One study on non-alcoholic fatty liver disease (NAFLD) has demonstrated a direct correlation between serum resistin levels and the severity of morphological changes in the liver [24] .
In the present study we evaluated associations between circulating resistin levels and humoral autoimmunity in a broad spectrum of pathological conditions of the gastrointestinal tract. Our results show increased levels of resistin in patients with breach of self-tolerance. We conclude that resistin may be an important determinant in autoantibody-mediated gastrointestinal inflammatory diseases.
MATERIAL AND METHODS

Patient population
227 patients were recruited from the Division of Gastroenterology and Hepatology, Linköping University Hospital, Linköping. Clinical and demographic characteristics of the patient groups and controls are shown in Table 1 . 50 patients were diagnosed with NAFLD based on the presence of biopsy-proven hepatic steatosis, self-reported alcohol consumption ≤140 g/week and no evidence of any other liver disease or medication associated with fatty infiltration of the liver as previously described [25] . 104 patients diagnosed with IBD consisted of 53 patients with UC and 51 with CD. The IBD diagnosis was based on standard clinical, endoscopic, radiological and histological findings [26] .
46 patients were diagnosed with AIH based on the revised AIH-score previously described [27, 28] . An AIH-score >17 corresponded to a definite AIH diagnosis whereas an AIH-score >11 corresponded to probable AIH. The mean score in the study group was 18.3±0.7 (range 10-26). 8/46 AIH patients (17%) had concomitant primary biliary cirrhosis (PBC), i.e. overlap between AIH and PBC. 27 patients were diagnosed with PSC, whereof 18 had concomitant UC, 4 AIH, 1 CD and 4 isolated PSC. The PSC diagnosis was based on standard biochemical, clinical and cholangiographic findings [29] . Onset of PSC was defined as the time of the first cholangiographic investigation consistent with a diagnosis of PSC. A group consisting of 40 apparently healthy controls (HC) served as reference. None of the control subjects had any history of autoimmune disorder or had used immunomodulatory drugs or antibiotics prior or at the time-point of blood sampling.
Serum sample collection
Venous blood samples from patients and controls were collected into heparinized tubes.
Samples were centrifuged at 800g for 15 min, aliquoted, and stored frozen at -80°C pending analysis.
Biochemical assessment
Biochemical assessment included levels of hemoglobin, platelet and white blood cells (WBC) counts, C-reactive protein (CRP) and serum immunoglobulins (total IgM, IgG and IgA). Liver function was evaluated based on measurement of alanine aminotransferase (65) 7 (26) (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (γ-GT) and bilirubin. In NAFLD patients, metabolic profile including body mass index (BMI), levels of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, homeostasis model of assessment for insulin resistence index (HOMA-IR) and thyroid hormones were determined. staining by the initial dilution were subjected to further analysis using serial dilutions (end-point titration). Cut-off was set at dilutions ≥1:80 based on the 95th percentile of serum materials from healthy donors.
Detection of autoantibodies
Resistin measurements
Serum resistin concentrations were determined using quantitative sandwich ELISA (R&D Systems, Abingdon, UK). Briefly, wells were coated with capture monoclonal mouse anti-human resistin antibodies (IgG2B clone 184335) 0.4 µg/ml. Sera were diluted 1:5 in 1% BSA-PBS. In the detection step biotinylated polyclonal antibodies were used (200 ng/ml). Resistin levels were quantified using a standard serial dilution of recombinant resistin. Colorimetric reaction was measured following addition of HRPsubstrate at a wavelength of 450 nm. Lowest detectable level was 15 pg/ml.
Measurement of cytokine levels
Levels of IL-6 and IL-8 were determined using quantitative sandwich ELISA (Quantikine HS, R&D Systems Europe Ltd., Abingdon, UK). Sera were diluted 1:25 in 1% BSA-PBS. In the detection step biotinylated polyclonal antibodies were used. Quantification of the cytokines was performed using a serial dilution of recombinant protein and expressed in ng/ml. Colorimetric reaction was measured following addition of HRP-substrate at a wavelength of 450 nm.
Statistics
Data are expressed as mean±SEM unless indicated otherwise. The degree of association was evaluated with Spearman rank correlation test. Comparisons between groups were assessed with the Mann-Whitney U-test. P-values <0.05 were considered significant. All statistical analyses were performed using SPSS for Windows (version 15.0.0; SPSS Inc.
(IBM), Chicago, IL, USA).
Ethics
The study protocol was approved by the Ethical Committee of the University Hospital of Linköping, and written informed consent was obtained from all the patients.
RESULTS
Serum resistin is elevated in patients with inflammatory gastrointestinal diseases
As demonstrated in Figure 1ab , resistin levels were significantly elevated in patients with inflammatory liver conditions, i.e. AIH (14.0±2.0 ng/ml), PSC (19.7±3.5 ng/ml) as compared to HC (7.0±0.6 ng/ml, p=0.017 and p=0.03, respectively) as well as to patients with NAFLD (6.7±0.8 ng/ml, both p<0.001). CD patients (16.9±3.0 ng/ml) showed higher resistin levels compared to NAFLD (6.7±0.8 ng/ml, p=0.041), while in patients with UC, resistin levels were similar to NAFLD (11.0±0.5 ng/ml). Resistin levels in patients with combined AIH and PBC (7.0±1.1 ng/ml, n=8) were similar to both NAFLD patients and controls. 
Elevated resistin levels are associated with antinuclear antibodies
Autoantibody status (ANA, AMA and SMA) in the patient groups is shown in Table 1 and resistin levels in relation to ANA in Figure 1b . In inflammatory diseases (UC, CD, AIH and PSC), resistin levels were significantly higher in ANA positive (n=35) compared to ANA negative (n=142) patients (16.9±2.7 ng/ml vs. 12.8±1.4 ng/ml, p=0.025; Figure 2a) ; where the best distinction was seen in IBD patients. As expected, the highest proportion of ANA positivity was found in AIH patients (48%) followed by PSC patients (22%), NAFLD (14%) and IBD (7%) patients. ANA titers showed no correlation to resistin levels (not shown). Within the AIH and PSC groups, resistin levels did not differ between ANA positive and negative patients. The presence of SMA was common in patients with AIH (63%), while AMA was found only in patients with overlap between AIH and PBC. No difference in resistin levels was seen in AIH patients having AMA or SMA without ANA, as compared to ANA positive and individuals without antibodies. Autoantibody status for the four inflammatory diseases combined (UC, CD, AIH and PSC) is shown in Figure   2b ; and in Table 2 
Resistin in NAFLD
Resistin levels in NAFLD patients (6.7±0.8 ng/ml) and HC (7.0±0.6 ng/ml) were not significantly different (Figure 1a) . No correlations between the levels of resistin and BMI, blood lipids, HOMA-IR or thyroid hormones in NAFLD patients were seen; and no difference concerning resistin levels between patients with steatohepatitis and simple fatty liver was found. Resistin was measured simultaneously with liver biopsy, which made a direct comparison with liver histology possible. As demonstrated in Table 3 , resistin levels showed no correlations with the intensity of fibrosis, fatty infiltration, nor to the intensity of inflammation. Thiopurine treatment, n (%) 20 (71)* 11 (44)* 11 (9) Steroide treatment, n (%) 3 (9) 6 (24) 15 (14) * p<0.05 as compared to "None" ANA=anti-nuclear antibodies, AMA=anti-mitochondrial antibodies, SMA=smooth muscle antibodies, CRP=C-reactive protein Table 3 .
Serum resistin levels and hepatic fibrosis demonstrated in the 50 patients with non-alcoholic fatty liver disease (NAFLD). Liver histology was scored by an independent pathologist according to the system developed by Brunt et al [41] . Resistin levels are given as means ± SEM. 
DISCUSSION
The present study has a cross-sectional design aiming at evaluating resistin levels in a broad spectrum of pathological conditions of the gastrointestinal tract. The number of included subjects is limited, and thus, interpretation of results requires a careful approach. Our data showed no clear association between resistin levels and disease activity in UC, CD or AIH, but still -and as expected -resistin levels were higher in inflammatory diseases, being most prominent in patients with hepatobiliary inflammation (AIH and PSC), whereas levels in liver disease associated with the Since no difference in resistin levels was found between ANA positive and negative individuals within the AIH group, it is unlikely that resistin could aid in discriminating AIH type 1 (AIH-1), which is often ANA and/or SMA positive, from AIH-2, usually ANA negative with autoantibodies to liver kidney microsomes and/or liver cytosol [30] .
However, AIH patients were significantly more often treated with corticosteroids (65%) and thiopurins (43%), compared to the other disease groups and it can not be excluded that this could have an impact on the resistin levels and partly explain the lack of a statistical distinction between ANA positive and ANA negative AIH patients.
The knowledge of the impact of pharmaceutical treatment on resistin levels per se is limited. However, in rheumatoid arthritis, anti-TNF therapy results in a rapid reduction of serum resistin and the levels of resistin follow CRP levels closely [31] . In asthma, raised resistin levels are found compared to healthy subjects; and levels are associated with disease severity (frequent symptoms/exacerbations and need for continuous antiobstructive therapy) [32] . Finally, local tissue secretion of resistin from adipose specimens was found to be significantly lower in CD patients receiving steroids compared to CD patients without steroids [20] .
T cell dependent mechanisms play an essential role in the pathogenesis of AIH and PSC [3] . Support for a relation between resistin and T cell function are provided by our previous findings of increased resistin expression in the foci of T lymphocytes in patients with primary Sjögren's syndrome [17] . Furthermore, resistin induces T cell migration in functional in vitro studies of human CD4 T cells, supporting the concept of macrophage-induced T cell chemotaxis [33] . Resistin also decreases T cell activity via decreased antigen uptake and endocytic capacity of human dendritic cells supporting its possible relation to T cell function [34] . Additionally, two other molecules of the resistinlike family (RELMα and RELMβ) [5] has been shown to augment T cell responses, suppressing IL-4 and IFN-γ production, during chronic intestinal inflammation in mice [35] . Potential modulating effects of resistin on T and B cells, leading to autoantibody production in hepatobiliary diseases, need further investigation.
Production of resistin at the site of inflammation is considered a response of innate cells,
i.e. macrophages [36] or neutrophils [37] , to exogenous stimuli. Resistin itself is capable of inducing NF-kB dependent inflammatory responses, which are reflected by the secretion of IL-6 and IL-8 [11] . A possible regulatory function of resistin in hepatobiliary diseases finds support in the present study where moderate correlations with proinflammatory cytokines (IL-6 and IL-8) were found. Resistin is expressed at low levels in hepatocytes and production of resistin may be induced through NF-kB-dependent cascade in stellate cells of human liver and in a Hep G2 cell line [38] . Moreover, human hepatic tissues respond to resistin with release of pro-inflammatory cytokines [38, 39] .
Other possible origins of resistin include infiltrating mononuclear cells, peripheral blood mononuclear cells, as well as resistin produced at remote organs by infiltrating myeloid cells. Thus, excessive levels of resistin in gastrointestinal diseases may have dual roles in the pathogenesis of autoimmune hepatobiliary diseases, inhibiting CD4 T cells as well as facilitating both autoantibody and cytokine production.
The observation of the regulatory effect of resistin in carbohydrate metabolism in mice [9] initiated attempts to identify resistin-dependent mechanisms of fat deposition and insulin resistance in humans [39] and, in fact, resistin has been described as a biomarker of insulin resistance and cirrhosis related to metabolic liver disease [40] . However, the findings in our well-characterized NAFLD cohort [25] do not provide evidence for association with either diabetes, insulin resistence or the extent of hepatic fibrosis.
In conclusion, we extend the knowledge regarding resistin expression in autoimmune conditions of the gastrointestinal tract. The results show increased resistin levels in patients with breach of self-tolerance, i.e. ANA positivity; and diagnoses with raised resistin (AIH, PSC and CD) were significantly associated with the need of more immunosuppressive treatment in form of steroids and thiopurines (the latter only significant for CD). Our interpretation is that resistin levels are associated with disease severity rather than disease activity. Thus, we propose that resistin could be a surrogate marker for disease severity in these conditions. We admit, however, that this study is small and that the observations need confirmation. To fully answer the question on how to position resistin analysis in the clinical situation, studies with consecutive samples from patients with "active" and "non-active" disease are warranted.
